BRPI1008885A2 - anticorpo, método para a produção de um anticorpo, uso do anticorpo, método para a produção de polipeptídeo de neurotoxina processado, métoro para a produção de um medicamento e composição - Google Patents
anticorpo, método para a produção de um anticorpo, uso do anticorpo, método para a produção de polipeptídeo de neurotoxina processado, métoro para a produção de um medicamento e composiçãoInfo
- Publication number
- BRPI1008885A2 BRPI1008885A2 BRPI1008885A BRPI1008885A BRPI1008885A2 BR PI1008885 A2 BRPI1008885 A2 BR PI1008885A2 BR PI1008885 A BRPI1008885 A BR PI1008885A BR PI1008885 A BRPI1008885 A BR PI1008885A BR PI1008885 A2 BRPI1008885 A2 BR PI1008885A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- producing
- medicament
- composition
- neurotoxin polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20798909P | 2009-02-19 | 2009-02-19 | |
| EP09153226 | 2009-02-19 | ||
| US61/207,989 | 2009-02-19 | ||
| EP091532267 | 2009-02-19 | ||
| US27517309P | 2009-08-26 | 2009-08-26 | |
| EP091686790 | 2009-08-26 | ||
| US61/275,173 | 2009-08-26 | ||
| EP09168679 | 2009-08-26 | ||
| PCT/EP2010/000985 WO2010094463A1 (en) | 2009-02-19 | 2010-02-17 | Means and methods for manufacturing highly pure neurotoxin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI1008885A2 true BRPI1008885A2 (pt) | 2016-03-15 |
| BRPI1008885B1 BRPI1008885B1 (pt) | 2021-09-28 |
Family
ID=42084499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1008885-7A BRPI1008885B1 (pt) | 2009-02-19 | 2010-02-17 | Método para obter uma solução purificada de polipeptídeos de neurotoxina processados e composição |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9447175B2 (pt) |
| EP (1) | EP2398824B1 (pt) |
| JP (1) | JP5795539B2 (pt) |
| KR (1) | KR101806567B1 (pt) |
| CN (1) | CN102325792B (pt) |
| AU (1) | AU2010214834B2 (pt) |
| BR (1) | BRPI1008885B1 (pt) |
| CA (1) | CA2751311C (pt) |
| IL (1) | IL214372A0 (pt) |
| MX (1) | MX340772B (pt) |
| RU (1) | RU2571212C2 (pt) |
| WO (1) | WO2010094463A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2266600B1 (en) * | 2004-07-26 | 2014-09-10 | Merz Pharma GmbH & Co. KGaA | Therapeutic composition with a botulinum neurotoxin |
| AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
| US9161970B2 (en) * | 2007-12-12 | 2015-10-20 | Allergan, Inc. | Dermal filler |
| ES2647243T3 (es) * | 2009-04-27 | 2017-12-20 | Merz Pharma Gmbh & Co. Kgaa | Medios y métodos para la determinación de la cantidad de polipéptido Neurotoxina y de sus actividades catalíticas y proteolíticas |
| ES2449303T3 (es) * | 2009-10-21 | 2014-03-19 | Merz Pharma Gmbh & Co. Kgaa | Sistema para la determinación de una neurotoxina tipo A no procesada y parcialmente procesada |
| KR102083371B1 (ko) | 2012-11-21 | 2020-03-04 | 입센 바이오이노베이션 리미티드 | 단백질 가수분해 처리된 폴리펩티드의 제조방법 |
| WO2014113249A2 (en) * | 2013-01-16 | 2014-07-24 | Kci Licensing, Inc. | Ion exchange enhanced absorbent systems |
| EP3154572A1 (en) * | 2014-06-13 | 2017-04-19 | Merz Pharma GmbH & Co. KGaA | Novel uses of recombinant clostridial neurotoxins with decreased duration of effect |
| GB201517450D0 (en) * | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
| RU2019110875A (ru) | 2016-09-13 | 2020-10-15 | Аллерган, Инк. | Небелковые композиции клостридиального токсина |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05501351A (ja) | 1989-08-16 | 1993-03-18 | カイロン コーポレイション | プロホルモンタンパク質に対する開裂部位阻止抗体及びその使用 |
| US6667158B1 (en) * | 1998-12-17 | 2003-12-23 | The United States Of America As Represented By The Secretary Of The Army | Antibodies against type a botulinum neurotoxin |
| US20090018081A1 (en) | 1999-08-25 | 2009-01-15 | Allergan, Inc. | Activatable clostridial toxins |
| GB9921592D0 (en) * | 1999-09-13 | 1999-11-17 | Microbiological Res Authority | Preparation of highly pure toxin fragments |
| US6678651B2 (en) | 2000-09-15 | 2004-01-13 | Mindspeed Technologies, Inc. | Short-term enhancement in CELP speech coding |
| AU2002228887B2 (en) * | 2000-11-06 | 2006-08-24 | United States Army Medical Research And Material Command | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
| AU2003304411A1 (en) * | 2002-08-01 | 2005-03-07 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| RU2230325C2 (ru) * | 2002-08-15 | 2004-06-10 | Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации | Способ приготовления очищенного препарата ботулинического токсина типа а |
| US20080171347A1 (en) * | 2003-04-11 | 2008-07-17 | Atassi M Zouhair | Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides |
| EP2266600B1 (en) * | 2004-07-26 | 2014-09-10 | Merz Pharma GmbH & Co. KGaA | Therapeutic composition with a botulinum neurotoxin |
| DE102005002978B4 (de) | 2005-01-21 | 2013-04-25 | Merz Pharma Gmbh & Co. Kgaa | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form |
| EP2049156B1 (en) | 2006-07-24 | 2013-09-25 | The Cleveland Clinic Foundation | Compositions and methods for macular degeneration |
| JP2008113592A (ja) * | 2006-11-02 | 2008-05-22 | Biseibutsu Kagaku Kenkyusho:Kk | クロストリジウム・パーフリンゲンスの産生する新規な毒素 |
| EP2048156A1 (en) * | 2007-10-12 | 2009-04-15 | Merz Pharma GmbH & Co.KGaA | Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin |
| CA2686637A1 (en) * | 2007-06-01 | 2008-12-04 | Merz Pharma Gmbh & Co. Kgaa | Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in solid form |
| US7732579B2 (en) * | 2007-06-13 | 2010-06-08 | The United States Of America As Represented By The Secretary Of Agriculture | High-affinity monoclonal antibodies for botulinum toxin type A |
| EP2178905B1 (en) * | 2007-07-26 | 2013-11-06 | Allergan, Inc. | Methods of activiting clostridial toxins |
-
2010
- 2010-02-17 KR KR1020117021889A patent/KR101806567B1/ko active IP Right Grant
- 2010-02-17 RU RU2011138060/10A patent/RU2571212C2/ru active
- 2010-02-17 AU AU2010214834A patent/AU2010214834B2/en active Active
- 2010-02-17 MX MX2011008759A patent/MX340772B/es active IP Right Grant
- 2010-02-17 CN CN201080008525.XA patent/CN102325792B/zh active Active
- 2010-02-17 EP EP10705297.9A patent/EP2398824B1/en active Active
- 2010-02-17 US US13/138,452 patent/US9447175B2/en active Active
- 2010-02-17 BR BRPI1008885-7A patent/BRPI1008885B1/pt active IP Right Grant
- 2010-02-17 CA CA2751311A patent/CA2751311C/en active Active
- 2010-02-17 JP JP2011550466A patent/JP5795539B2/ja active Active
- 2010-02-17 WO PCT/EP2010/000985 patent/WO2010094463A1/en active Application Filing
-
2011
- 2011-07-31 IL IL214372A patent/IL214372A0/en active IP Right Grant
-
2016
- 2016-08-08 US US15/230,928 patent/US9963502B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL214372A0 (en) | 2011-09-27 |
| MX2011008759A (es) | 2011-09-09 |
| KR20110122852A (ko) | 2011-11-11 |
| KR101806567B1 (ko) | 2018-01-10 |
| EP2398824B1 (en) | 2018-12-26 |
| RU2571212C2 (ru) | 2015-12-20 |
| MX340772B (es) | 2016-07-26 |
| CN102325792B (zh) | 2018-01-09 |
| US20160340417A1 (en) | 2016-11-24 |
| CA2751311C (en) | 2019-08-06 |
| EP2398824A1 (en) | 2011-12-28 |
| US9963502B2 (en) | 2018-05-08 |
| CA2751311A1 (en) | 2010-08-26 |
| AU2010214834A1 (en) | 2011-08-18 |
| CN102325792A (zh) | 2012-01-18 |
| JP2012518018A (ja) | 2012-08-09 |
| US9447175B2 (en) | 2016-09-20 |
| RU2011138060A (ru) | 2013-03-27 |
| AU2010214834B2 (en) | 2016-04-14 |
| US20120004179A1 (en) | 2012-01-05 |
| WO2010094463A1 (en) | 2010-08-26 |
| BRPI1008885B1 (pt) | 2021-09-28 |
| JP5795539B2 (ja) | 2015-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1008885A2 (pt) | anticorpo, método para a produção de um anticorpo, uso do anticorpo, método para a produção de polipeptídeo de neurotoxina processado, métoro para a produção de um medicamento e composição | |
| BR112015002091A2 (pt) | método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição | |
| BRPI1010775A2 (pt) | composição, método para preparar uma composição, e, uso de uma composição. | |
| BRPI1014253A2 (pt) | polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento | |
| BR112012000296A2 (pt) | composição e método para produção de um propante cerâmico ultraleve. | |
| BR112015007120A2 (pt) | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo | |
| BR112014016047A2 (pt) | composição de compósito degradável, composição, e método de uso um compósito degradável | |
| BRPI1005322A2 (pt) | anticorpo, composição farmacêutica e uso de pelo menos um anticorpo | |
| BR112015006824A2 (pt) | anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico | |
| BR112014012624A2 (pt) | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo | |
| BR112014003802A2 (pt) | composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento | |
| BRPI1006141A2 (pt) | composições de anticorpo modificado, métodos para preparar e usar as mesmas | |
| CL2011002943A1 (es) | Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica. | |
| BR112013023653A2 (pt) | anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica | |
| BRPI0922174A2 (pt) | preparação farmacêutica, uso de uma preparação, e, método para preparar uma preparação farmacêutica | |
| BRPI1008971A2 (pt) | métodos para preparar uma proteína biológica condicionalmente ativa, e um modificador de resposta biológica condicionalmente ativo, proteína biológica condicionalmente ativa, e, composição farmacêutica | |
| BR112012026570A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado | |
| BRPI1007867A2 (pt) | anticorpos para troponina i e método s de uso para os mesmos | |
| BR112014001346A8 (pt) | composto nanotransportador, método, composto farmacêutico e uso de um composto | |
| BR112013030163A2 (pt) | composto, uso cosmético de pelo menos um composto, composição farmacêutica ou cosmética e processo para preparar um composto. | |
| BRPI1008145A2 (pt) | proteína de ligação de antígeno biespecífico, método para preparação de uma proteína de ligação de antígeno biespecífico, célula hospedeira, composição farmacêutica, uso da proteína de ligação de antígeno biespecífico e método para o tratamento de um paciente. | |
| BR112015002263A2 (pt) | polipeptídeo de fusão, polipeptídeo de fusão dimérico, método para a produção de um receptor fc solúvel, uso de um polipeptídeo de fusão imobilizado e composição farmacêutica | |
| BR112012025375A2 (pt) | compósito absorvente, artigo de cuidade pessoal absorvente e método para preparação de um artigo de cuidado pessoal absorvente | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| BR112013006092A2 (pt) | laminado, matéria-prima do laminado, método para preparação de um laminado e uso do laminado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/02/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |